Tevogen Bio is driven by a team of highly experienced industry leaders and distinguished scientists with drug development and global product launch experience. Tevogen Bio’s leadership believes that ...
6d
GlobalData on MSNUSPTO grants patent to Vistagen’s neuropathic pain treatmentThe USPTO has granted a patent to Vistagen’s non-opioid oral product candidate AV-101 for neuropathic pain treatment.
Hosted on MSN1d
Royalty Pharma (NASDAQ:RPRX) Misses Q4 Revenue EstimatesHealthcare royalties company Royalty Pharma (NASDAQ:RPRX) in Q4 CY2024, with sales flat year on year at $594 million. Its ...
New DTC platforms like LillyDirect and PfizerForAll are triggering a paradigm shift in how pharma companies connect with patients.
India's future is being shaped by a new wave of innovative companies revolutionizing industries through technology, creativity, and purpose-driven leadership. From mental healthcare to digital ...
StockStory.org on MSN6d
Eli Lilly (NYSE:LLY) Reports Q4 In Line With Expectations, Full-Year Outlook Slightly Exceeds ExpectationsGlobal pharmaceutical company Eli Lilly (NYSE:LLY) in Q4 CY2024, with sales up 44.7% year on year to $13.53 billion. The ...
Humana's 2024 earnings reveal revenue growth but major structural issues impacting profitability. Learn about risks, new ...
In a relatively short time, RFK Jr. has forced America to begin to recognize that the food choices they make have significant ...
Like many industries, the pharmaceutical labour market has felt and will continue to feel the impacts of the COVID-19 pandemic moving into 2023 and beyond. A new operating model for pharma shifted ...
The pharma industry is often thought of as one that ... When this is combined with a high-volume, low-margin business model, the impact could be outsized when compared against other companies ...
| With budget reconciliation right around the corner, different slices of the healthcare industry have made their views clear on issues like physician pay, ACA subsidies, telehealth flexibilities, ...
Right after the end of the AI Action Summit in Paris, Anthropic’s co-founder and CEO Dario Amodei called the event a “missed opportunity.” He added that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results